PL371327A1 - Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) - Google Patents

Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Info

Publication number
PL371327A1
PL371327A1 PL03371327A PL37132703A PL371327A1 PL 371327 A1 PL371327 A1 PL 371327A1 PL 03371327 A PL03371327 A PL 03371327A PL 37132703 A PL37132703 A PL 37132703A PL 371327 A1 PL371327 A1 PL 371327A1
Authority
PL
Poland
Prior art keywords
ifn
interleukin
interrupting
immune reactions
reactions induced
Prior art date
Application number
PL03371327A
Other languages
Polish (pl)
Inventor
Thorsten Blume
Wolf-Dietrich Döcke
Wolfgang Halfbrodt
Joachim Kuhnke
Ursula Mönning
Bernd Elger
Herbert Schneider
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL371327A1 publication Critical patent/PL371327A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03371327A 2002-02-15 2003-01-17 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) PL371327A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (en) 2002-02-15 2002-02-15 Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses

Publications (1)

Publication Number Publication Date
PL371327A1 true PL371327A1 (en) 2005-06-13

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03371327A PL371327A1 (en) 2002-02-15 2003-01-17 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Country Status (21)

Country Link
EP (1) EP1474138A1 (en)
JP (1) JP2005522447A (en)
KR (1) KR20040084909A (en)
CN (1) CN1756546A (en)
AR (1) AR039556A1 (en)
AU (1) AU2003245523A1 (en)
BR (1) BR0307706A (en)
CA (1) CA2475770A1 (en)
DE (1) DE10207843A1 (en)
EC (1) ECSP045297A (en)
MX (1) MXPA04007943A (en)
NO (1) NO20043840L (en)
PE (1) PE20030906A1 (en)
PL (1) PL371327A1 (en)
RS (1) RS71304A (en)
RU (1) RU2004127677A (en)
TW (1) TW200306823A (en)
UA (1) UA81111C2 (en)
UY (1) UY27662A1 (en)
WO (1) WO2003068225A1 (en)
ZA (1) ZA200407382B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (en) * 2002-02-15 2003-09-04 Schering Ag 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives
WO2006097547A1 (en) * 2005-03-17 2006-09-21 Proyecto De Biomedicina Cima S.L. Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
BR112014030940B1 (en) * 2012-06-11 2022-09-06 UCB Biopharma SRL BENZIMIDAZOLS THAT MODULATE TNF-ALFA AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
PL3371190T3 (en) 2015-11-06 2022-11-07 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
PL3390367T3 (en) * 2015-12-15 2021-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
AR107293A1 (en) 2016-01-05 2018-04-18 Incyte Corp PIRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-g INHIBITORS
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JP7244504B2 (en) 2017-10-18 2023-03-22 インサイト・コーポレイション Fused Imidazole Derivatives Substituted with Tertiary Hydroxy Groups as PI3K-γ Inhibitors
CR20210165A (en) 2018-09-05 2021-10-01 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
FI3860998T3 (en) 2018-10-05 2024-03-27 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity
CN112341451B (en) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 Immunomodulator
CN112341450B (en) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 Immunomodulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (en) * 1993-09-09 1995-03-16 Schering Ag New benzimidazole derivatives, processes for their preparation and their pharmaceutical use
MXPA02005742A (en) * 2000-01-14 2002-09-18 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation.
DE10134775A1 (en) * 2001-07-06 2003-01-30 Schering Ag 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
AR039556A1 (en) 2005-02-23
NO20043840L (en) 2004-11-12
UY27662A1 (en) 2003-09-30
DE10207843A1 (en) 2003-09-04
ZA200407382B (en) 2005-09-14
EP1474138A1 (en) 2004-11-10
CN1756546A (en) 2006-04-05
KR20040084909A (en) 2004-10-06
JP2005522447A (en) 2005-07-28
ECSP045297A (en) 2004-10-26
CA2475770A1 (en) 2003-08-21
MXPA04007943A (en) 2004-11-26
WO2003068225A1 (en) 2003-08-21
TW200306823A (en) 2003-12-01
BR0307706A (en) 2005-01-11
RU2004127677A (en) 2005-06-10
UA81111C2 (en) 2007-12-10
PE20030906A1 (en) 2004-01-17
RS71304A (en) 2006-10-27
AU2003245523A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
GB0209511D0 (en) Computer system and method
HK1095181A1 (en) Modular computer system and components therefor
AU2002234755A1 (en) Interferon-alpha induced gene
IL136454A0 (en) Compositions and methods for inducing gene expression
PL371327A1 (en) Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
HK1069834A1 (en) Interferon gamma polypeptide variants
IL172294A0 (en) Methods and compositions for interferon therapy
GB2389386B (en) Fall protection system and apparatus
AU2003226090A1 (en) Page indexing system and apparatus for forming page shapes of system
AU2002325433A8 (en) Method for correcting immune responses and medicinal agent
IL159287A0 (en) Tablet comprising cetirizine and pseudoephedrine
EP1386674A4 (en) Structure cleaning method and anticorrosion method; and structure using them
AU2002363522A8 (en) System and method for improved computer drug design
AU2003225710A8 (en) Composition and method for enhancing immune response
AU2002366809A8 (en) Syn3 compositions and methods
IL158440A0 (en) Vaccines including as an adjuvant type 1 ifn and processes related thereto
PL359562A1 (en) Interferon for treatment of multiple sclerosis
HUP0001976A3 (en) Antiviral protease inhibitors and pharmaceutical compositions
GB0030184D0 (en) Interferon alpha induced gene
GB0112453D0 (en) Interferon-alpha induced gene
AU2003297297A8 (en) Elf3 gene compositions and methods
GB0218473D0 (en) Interferon-alpha induced gene
GB0200619D0 (en) Interferon-alpha induced gene
GB0104706D0 (en) Interferon - alpha induced gene
HK1065782A1 (en) Compositions comprising higher diamondoids and processes for their separation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)